, | ||||||||||||||||
V | 115 1) (35) 2) (35) 3) (45) | - | 2 : | : , , | ||||||||||||
IV | 62 1) (32) 2) (30) | : NIHSS, Rankin, Barther | , , . | : , | ||||||||||||
III | 76 () I-II 1) (45) 2) (31) | , , , , | : , , | |||||||||||||
III | 60 I-II , 1) (30) 2) (30) | (GCI) Euro-Qol5D | : , , - | : , , . - , | ||||||||||||
VI | 273 : | 1) Mini Mental Scale 2) Sandoz, 19 7- 3) 4) [13] ( ) 5) 6) Euro-Qol5D | , , , , , , | : , .. , , | ||||||||||||
VI | 187 : | ; , | , , | : : , , . | ||||||||||||
I | 1002 , , - | 1) 2) | ( ) , , , , | : , | ||||||||||||
III | 158 1) 2) 1) | ( Barthel, Kuriansky), (Aachen Aphasia Test) (Rivermead Perception Assessment Battery) | Aachen Aphasia Test 12- | C: , | ||||||||||||
PASS [44] | III | 927 1) 2) 2) | , | : , | ||||||||||||
II | 19 - | ; (GCI) | : - | |||||||||||||
II | 130 , 2 1) 2) | (GCI), , Sandoz (SCAG), , BGP, STK | , . | : , | ||||||||||||
II | 109 . 1) 2) | 19 | , , 19 , , , | : , | ||||||||||||
I | - - , 2000 . ( ) | (GCI) | , . GCI. , , . | : , | ||||||||||||
I | 62 : (41), (21) | , , | , ( 1 ) | : | ||||||||||||
( ) | ||||||||||||||||
II | 7 : 1963 , 14 | 54,6% 66,4% | : - | |||||||||||||
II | 4 , 1652 | , , : NIHSS; RS; Barthel; | 25,2% 20,2% 3 | : - | ||||||||||||
II | 2 , 214 1) , 500 2) , 2000 3) | , 24 12 | 12- 84,7%, 500 34,0%, 2000 1,8%. | , - 2 . | ||||||||||||
ICTUS [37] | III | 2298 : 1148 , 1150 - | , , : NIHSS; RS; Barthel | 2078 , .. . | : | |||||||||||
III | 33 , , - 1) 500 2) | NIHSS; RS; Barthel; | , | : . | ||||||||||||
I | 14 , - . | (GCI) | . , . | : , . , | ||||||||||||
III | 30 ( ) 1) 1000 (13) 2) (17) | ; | : . - | |||||||||||||
CORBIT [22] | III | 1213 , 1) 2) | , | : . | ||||||||||||
( ) | ||||||||||||||||
III | 146 1) (78) 2) (68) | Barthel (BI) (GCI) | : , | |||||||||||||
III | 60 : 1) (28) 2) (32) | (GNS); (GCI); Rankin (mRS) . 28 | 28 . 1 , | : . - | ||||||||||||
III | 60 : 1) 10 (20) 2) 50 (20) 3) (20) | NIHSS, Barthel (BI); Rankin (mRS); (GCI) (KOS) | NIHSS (BI), | : . - | ||||||||||||
III | 47 1) 50 (24) 2) (23) | - () 3- 28- NIHSS, Barthel (BI) Rankin (mRS) (CGI) | ; , | : . - | ||||||||||||
CERELYSE-1 [27] | III | 119 , 1) 30 (60) 2) (59) | Rankin (mRS) NIHSS, Barthel (BI) (GOS) | 30- , , 90- | : , | |||||||||||
CASTA [28] | III | 1070 1) 30 (529) 2) (541) 10 | 90- Rankin (mRS) NIHSS, Barthel (BI) | , NIHSS BI | : | |||||||||||
III | 208 1) 10 (104) 2) (104) | ARAT 90- Rankin (mRS) NIHSS, Barthel (BI) . SF-36 | , 72 , , , | : , | ||||||||||||
I | 6 , 597 | (MMSE) (CGI) ADAS cog+ | , : , | : , , | ||||||||||||
III | 157 : 1) 30 (74) 2) (83) | (MMSE) (CGI) (Hamilton Depression Scale (HamD) . (SCAG, NAI .) | , | : , | ||||||||||||
II | 6 | (CGI) | GI, | : , | ||||||||||||
III | 217 : 1) (70) 2) (75) 3) + (72) | (CIBIC+) (ADAS-cog+, ADCS-ADL) | (+) . , , | : , | ||||||||||||
III | 279 : 1) 10 (69) 2) 30 (70) 3) 60 (71) 4) (69) | (CIBIC+) (ADAS-cog+) | 10 30 . 60 | : , | ||||||||||||
III | 44 : 1) (22); 2) (22) * * | (CGI) (GCS); (SST) | , , , . | : . - | ||||||||||||
. - . 6 , 2: [6,7]. ( , ..) ( , - ). , 2 .
|
|
|
|
|
|
|
|
6 V ( ), 2 , 1 - 1 . : , . , , .
|
|
. 8 , 2 : [8] [13]. , , , .
[13] .
- 38 , 1 - [10], 19 . .
Ȼ 200 . 4 : 2 [10,39], 2 [11,12]. ( II) [9] (PASS, 1999 .) [39].
[10-12] .
, - . , , (62 ). .. . [14] , , .
. [20], 14 . - 3 [16-18] . , . .
Ȼ 60 , 6 : 2 [19,37], 1 [21] 1 [22]. -, . 2012 . . Davalos . [37], , , . .
[21] , . (30 ), .
1 - [22] (1213 ); , .
. 1 [36]. . : , .
1 -, 6 , [30]: .
73 , - 11 II, 7 . 1070 [28], , , 90- , .
[34] . 2 - : R. Cacabelos (2008) [31] , . 2003 . , : 10 30 [32]. , , , . (44 ) .
, ( ), . .
I (- ). , . , , , . II (, ). , ; , . , .
: 3 - ( I). ( , ) , , . , , , . II (, - 1000 - ), , .
2 I (- ) , . (2013), . . , . , 72 . , , . 1 ( II 44 ), , , . .
, , (, ) 4 ( I II). V , , .
, , , , - , , . , . . , , , .
1. .., .. // . . ... 2007..107. 2. . 21-24.
2. .., .. , .. . - . . .,2008. . 98.
3. .., .., .. . // . . .. . 2006. Suppl. 17. .52-56.
4. .., .., .. // . . .. . 2008. Suppl. 22. . 32-38.
5. .., .., .., .. // . . 1999. 4. . 4245.
6. .., .. // : . . . .64-70.
7. . . .., .., .. . // . . .. .2006. 5.
8. Ricci S., Celani MG., Cantisani TA. // Cochrane Database Syst. Rev. 2012 Sep 12;9: CD000419. doi: 10.1002/14651858.CD000419.pub3.
9. Enderby .// Clin. Neuropharmacol. 1994. Vol. 17. 4. P. 320.
10. Waegemans T., Wilsher CR., Danniau A. : - //Dement. Geriatr. Cogn. Disord. 2002. Vol.13. 4. P.217-224.
11. Herrmann W.M., Stephan K. Moving from the question of efficacy to the question of therapeutic relevance: an exploratory reanalysis of a controlled clinical study of 130inpatients with dementia syndrome taking piracetam // J. Int. Psyhogeriatr. 1992. 4(1). P.25-44.
12. Lloyd-Evans S., Brocklehurst J.C., Palmer M.K. et al. // J. Curr. Med. Res.Opin. 1979. 6(5). P. 351-357.
13. Flicker L., Grimley Evans G. // Cochrane Database Syst Rev. 2001(2):CD001011.
14. .., .., .. // . . .. . 2010. 12. . 60-66.
15. Belcastro V., Costa C., Galletti F. : // Eur. J. Neurol. 2007. 10. P. 1176-1178.
16. Saver J.,Wilterdink J. : -. XXVII , . . 24 2002.
17. Davalos A., Castillo J., Varez-Sabin J. et al. : // J. Stroke. Vol.33.12. P. 2850-2857.
18. Warach S., Harnett K. . XXVII , . . 24 2002.
19. Clark W.M., Williams B.J., Selzer K.A. // J. Stroke. 1999. Vol.30.12.P.2592-2507.
20. Fioravanti M, Yanagi M. , // Cochrane Database Syst. Rev. 2005 Apr 18;(2):CD000269.
21. Alvarez X.A., Mouzo R., Pichel V. et al. - : , // J. Meth. Find. Exp. Clin. Pharmacol. 1999. Vol.21. 9. P. 633-644.
22. Zafonte R.D., Bagiella E., Ansel B.M. : Citicoline Brain Injury Treatment Trial (COBRIT) // JAMA. 2012. Vol.308.19. P. 1993-2000.
23. Ladurner G, Therapeutic Efficacy of Cerebrolysin in Patients with an Ischaemic Stroke Efficacy in the Acute and Early Rehabilitation Phase. Final report. 2000. 1..44.
24. Wege W, Study to test the efficacy of Cerebrolysin in early rehabilitation patients after acute stroke. Final report. 2000.
25. .., .., .. . // . . . . .. . 2004. 11.
. 51-55.
26. .. 50 . . 2008.
27. Lang W. - // Final. Report. 1. 2009.
28. Hong Z. A // Final Report. EBE-CN-050823.2011.
29. Muresanu D. ( CARS): - , II // Final report. 2011.
30. Wei ZH, He QB, Wang H et al. // J. Neural. Transm. 2007. 5. . 629-634.
31. Cacabelos R. () . . . 2008.
32. Cacabelos R. , - - 3 . . . 2003.
33. König P., Waanders R., Witzmann A. et al. // J. Neurol. Neurochir. Psychiatr. 2006. 7(3). : 12-20.
34. Xiao S, Yan H, Peifen Y and the Cerebrolysin Study Group. : , , , // Hong Kong J. Psychiatry. 1999. 2. . 13-19.
35. .. // . 2007. 7. .3-4.
36. Chen N., Yang M., Guo J. et al. Cerebrolysin for vascular dementia // Cochrane library. 2012.
37. Davalos A., Alavares-Sabin J., Castillo S. et al. : , , - (ICTUS) // Lancet. 2012. Vol. 28.380(9839).P.349-357. doi: 10.1016/S0140-6736(12)60813-60817
38. RLS: http://www.rlsnet.ru/fg_index_id_46.htm.
39. Orgogozo JM. Piracetam in the treatment of acute stroke // J. Pharmacopsyhiatry.1999. Vol.32.1. P. 25-32.
40. : http://www.ceraxon.ru/
41. -- , 2013 . http://arvt.ru/sites/default/files/gov_2199p.pdf
42. http://www.about-health-care.com/homemed_page/gl_17/homemed_gl_17_r2.html
43. .., .., .. : // http://www.rmj.ru/articles_7762.htm
44. De Reuck J, Van Vleymen B PASS (Piracetam in Acute Stroke Study), 1999
45. http://www.rspor.ru/index.php?mod1=formular&mod2=db1&mod3=db2
46. .., .. - // . 2004. 6. .3-12.
47. .., .. // . 2004. 6. .3-12.
48. .. - ( , ) // . 2004. 7. .82-114.
49. .. , , // . 2005.9. .3-7.
50. , 20 2010..